English Extended Distribution iCN Internal Distribution Market Research Reportedtimes Research Newswire Wire

Oseltamivir Market to Grow at a CAGR of 3.17% During Forecast Period 2020-2025

oseltamivir market to grow at a cagr of 3 17 during forecast period 2020 2025

Oct 22, 2020 2:00 PM ET
Oseltamivir Market t

iCrowd Newswire – Oct 22, 2020

Oseltamivir Market size is forecast to reach $694.3 million by 2025, growing at a CAGR of 3.17% during the forecast period 2020-2025. Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B. Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. It helps make the symptoms like stuffy nose, cough, sore throat, fever/chills, aches, and tiredness less severe and shortens the recovery time by 1-2 days. Oseltamivir acts as neuraminidase inhibitor of the influenza virus, by preventing its reproduction by budding from the host cell. This also prevents the cleavage of sialic acid residues, thus interfering with progeny virus disbursement within the mucosal secretions and reducing viral infectivity. Growing incidences of influenza among the population, increasing awareness about the prevention, and increasing investments in novel drug combinations by big investment firms are major factors that are driving the market growth in recent years. In addition, major developments by key market players like Alembic Pharmaceuticals are other factors driving the growth of the market.

Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=501917

Report Price: $ 4500 (Single User License)  

Indication – Segment Analysis

Influenza A held the largest share in the indication segment of Oseltamivir Market in 2019 and is estimated to grow at a CAGR of 2.71% during the forecast period 2020-2025. Factors that contribute to the growth of this segment are the increasing prevalence of the disease and recent FDA approval of products by various companies for oral and other forms of dosage for influenza A. Also, spread of influenza A in other living beings (compared to influenza B which occurs only in human beings), and more severe reactions have led to demand for more and better medication by Oseltamivir drug, hence fueling market growth. Influenza B held the second largest share in the market, owing to a large percentage of influenza patients being affected by influenza B and more preference to Oseltamivir for its treatment. Influenza A segment is set to be the fastest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025, owing to major investments in medications for treatment of Influenza A by key market players.

Distribution Channels – Segment Analysis

Hospital Pharmacies segment held the major share in the distribution channels segment of Oseltamivir Market in 2019. Specialty drugs spend, next-door healthcare, increased focus on 340B performance and compliance, tracking and managing data and public policy with greater transparency are driving the market growth of this segment. Online Pharmacies segment is forecast to continue growing at the fastest rate with the highest CAGR during the forecast period 2020-2025, owing to growing trends in digital services and favorable government policies for online retails of medicines.

Geography – Segment Analysis

North America dominated the geography segment of Oseltamivir Market with a share of more than 37.41% in 2019, followed by Europe. Growing prevalence of influenza, increasing healthcare affordability of the masses and government initiatives for increasing awareness about prevention and treatment of influenza have helped in the growth of Oseltamivir Market infrastructure in this region. Europe held the second place in the geography segment share of the market, owing to presence of government guidelines for maintaining health of the population and presence of well-developed healthcare infrastructure.

However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025. This is owing to the growing drug market, gradually increasing awareness about the medications of influenza and entry of big investment firms in the region.

Talk to one of our sales representative about the full report by providing your details in the link below:


Drivers – Oseltamivir Market

  • Rising numbers of influenza cases among the population

The proportion of people who get sick from influenza has increased over the years. A survey report found that between 3% and 11% of the U.S. population gets infected and develops Influenza A or B each year. The 3% estimate is from the 2015-2016 season, which was an H1N1-predominant season classified as being of medium to high severity. With the growing statistics of the disease in the population at present, this is set to drive the market growth in the coming years.

  • Increasing awareness programs about Influenza

WHO/Europe launched the Flu Awareness Campaign initiative in 2013 as an extension of European Immunization Week. Influenza is usually mild and most people recover quickly. However, this contagious respiratory illness caused by influenza viruses occasionally cause severe disease and death. The best way to prevent influenza is by getting vaccinated. In order to make people aware, the campaigns serve the way for treatment with medications like Oseltamivir. As such, the market is poised to see significant growth during the forecast period 2020-2025.

Challenges – Oseltamivir Market

  • Side effects of Oseltamivir

Common side effects of Oseltamivir include nausea, vomiting, diarrhea, dizziness, headache, nosebleed, eye redness or discomfort and sleep problems (insomnia). This creates a negative impact on the demand of Oseltamivir among patients and buyers. Thus, it is anticipated to hamper the market growth during the forecast period 2020-2025.

Acquisitions/Product Launches

  • In June 2019, the US Food and Drug Administration approved Alembic Pharmaceuticals’ abbreviated new drug application for Oseltamivir phosphate capsules USP, 30 mg, 45 mg, and 75 mg.
  • In July 2019, Sanofi signed strategic deal for exclusive US over-the-counter rights to Tamiflu in Flu Care.
  • In December 2016, Natco Pharma, and partner Alvogen launched the “first generic equivalent” of Roche’s Tamiflu (Oseltamivir) in the U.S. The US FDA approved India based Natco Pharma and its US partner Alvogen’s application for a generic of Tamiflu.

Key Takeaways

  • North America dominated the Oseltamivir Market in the year 2019 owing to large number of cases of the population infected with influenza, increasing healthcare affordability of the majority population and government initiatives, presence of key market players in the region and funds for better innovations in the drug market. The Oseltamivir Market scope for different regions will be provided in the final report.
  • Rising numbers of influenza cases among the population, increasing awareness programs about the prevention and treatment of influenza, and increasing investments in novel drug combinations by big investment firms and key players in the market have helped in significant growth of Oseltamivir Market.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Oseltamivir Market report.
  • Side effects of Oseltamivir is anticipated to hamper the market growth of the Oseltamivir Industry.

Oseltamivir Industry Outlook

Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the Oseltamivir Market. In 2019, Oseltamivir Market share is consolidated by the top players present in the market. Oseltamivir Market top 10 companies are Cipla Inc, Sanofi, Hetero Healthcare Ltd, Lotus International, Md Export, Nagar Medico, Alembic Pharmaceuticals, Shivam Pharma Export, Natco Pharma and Triveni Chemical, among others.

Related Reports:

Position sensor Market


Prenatal Testing & Newborn Screening Market 


About IndustryARC : IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.

Contact Information:

Venkat Reddy
Sales Director
Email: [email protected]
Website: https://www.industryarc.com
Phone: (+1) 970-236-3677


Keywords:    Oseltamivir Market, Oseltamivir Market size, Oseltamivir Market industry, Oseltamivir Market share, Oseltamivir top 10 companies, Oseltamivir Market report, Oseltamivir Market industry outlook